CareTrust

CareTrust REIT Reports $119 Million in New Investments and Strengthens Acquisition Pipeline

CareTrust REIT, Inc. Expands Investment Activity with $119 Million in New Deals CareTrust REIT, (“CareTrust” or the “Company”) has announced the successful closing of two significant investment transactions totaling approximately $119 million, both effective April 1, 2026. These deals underscore…

Read MoreCareTrust REIT Reports $119 Million in New Investments and Strengthens Acquisition Pipeline
Xponential

Xponential Fitness Explores Strategic Options to Enhance Shareholder Value

Xponential Fitness Launches Strategic Review and Strengthens Board with New Appointment Xponential Fitness, a leading global franchisor of boutique health and wellness brands, has announced a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The initiative underscores the…

Read MoreXponential Fitness Explores Strategic Options to Enhance Shareholder Value
Agenus

Agenus to Present Phase II Data on BOT+BAL with Agent-797 in PD-1–Refractory Gastroesophageal Cancer at AACR 2026

Agenus to Present Phase II Data on Novel BOT+BAL and agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 Agenus a biotechnology company focused on advancing immuno-oncology therapies, has announced that new clinical data from an investigator-initiated Phase II…

Read MoreAgenus to Present Phase II Data on BOT+BAL with Agent-797 in PD-1–Refractory Gastroesophageal Cancer at AACR 2026
GenSight

GenSight Biologics Reports Full-Year 2025 Financial Results in Line with Expectations

GenSight Biologics Confirms Full-Year 2025 Financial Results in Line with Prior Estimates GenSight Biologics a clinical-stage biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has confirmed that its final consolidated financial results…

Read MoreGenSight Biologics Reports Full-Year 2025 Financial Results in Line with Expectations
Allevion

Allevion Medical Secures 510(k) Clearance for Vantage Disposable Kit, Advancing Spinal Decompression

Allevion Medical Secures FDA Clearance for Vantage™ Disposable System for Spinal Decompression Allevion Medical has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its innovative Vantage™ system, a fully disposable and sterile solution designed…

Read MoreAllevion Medical Secures 510(k) Clearance for Vantage Disposable Kit, Advancing Spinal Decompression